MARKET

IOVA

IOVA

Iovance Biotherp
NASDAQ
2.730
-0.040
-1.44%
After Hours: 2.760 +0.03 +1.10% 19:35 12/31 EST
OPEN
2.710
PREV CLOSE
2.770
HIGH
2.830
LOW
2.690
VOLUME
11.18M
TURNOVER
--
52 WEEK HIGH
8.15
52 WEEK LOW
1.639
MARKET CAP
1.08B
P/E (TTM)
-2.2714
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IOVA last week (1222-1226)?
Weekly Report · 12/29/2025 09:08
Iovance Biotherapeutics: Bright Prospects For 2026
Seeking Alpha · 12/29/2025 05:51
Weekly Report: what happened at IOVA last week (1215-1219)?
Weekly Report · 12/22/2025 09:08
Iovance Biotherapeutics Grants Inducement Stock Options to New Employees
Reuters · 12/19/2025 22:15
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Barchart · 12/19/2025 16:15
Iovance Biotherapeutics Is Maintained at Overweight by Barclays
Dow Jones · 12/17/2025 17:55
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $10
Benzinga · 12/17/2025 17:45
Iovance Biotherapeutics Advances Innovative Melanoma Treatment with Updated Study
TipRanks · 12/17/2025 16:33
More
About IOVA
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.

Webull offers Iovance Biotherapeutics Inc stock information, including NASDAQ: IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IOVA stock methods without spending real money on the virtual paper trading platform.